Loading
ENV-501 is an experimental antibody-drug conjugate from Hummingbird Bioscience in phase 2 trials for melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, aimed at HER3.
ENV-501 is an antibody-drug conjugate developed by Hummingbird Bioscience. Its target is HER3. ClinicalTrials.gov describes the intervention as: ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer. The largest, NCT06956690, plans to enrol 180 participants with primary completion expected 2027-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Antibody-drug conjugate directed at HER3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to HER3.
1.ENV-501's antibody arm binds HER3 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ENV-501" OR ABSTRACT:"ENV-501") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ENV-501, not a curated reading list.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares HER3, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.